Abbott Libre Duo CE Mark 2026: Continuous Glucose-Ketone Sensor and the CGM Market Evolution

Abbott Libre Duo: A Regulatory Milestone in Diabetes Technology

On May 27, 2026, Abbott (NYSE: ABT) secured CE marking for Libre Duo and Libre Duo 10 Day — the world's first continuous glucose-ketone sensing systems for people with diabetes. The dual-analyte biowearable sensors continuously monitor both glucose and ketone levels every minute through a single wearable sensor, providing real-time visibility into metabolic status that was previously only possible through intermittent blood or urine tests.

The CE mark covers two configurations:

• Libre Duo: Up to 15 days of continuous wear, intended for adults ages 18 and older
• Libre Duo 10 Day: Up to 10 days of continuous wear, intended for people ages 2 and older (clinical data indicated that a shorter wear period helps active youth complete the full sensor session)

Abbott plans to launch Libre Duo systems in select European countries later in 2026. The devices are also under review by the U.S. FDA, with CEO Robert Ford stating during Abbott's Q1 2026 earnings call that FDA approval is expected in the second half of 2026.

This article examines the regulatory strategy behind the Libre Duo approval, the clinical need it addresses, the competitive CGM market landscape, and what the convergence of continuous monitoring and wearable technology means for the medical device industry.

Why Continuous Ketone Monitoring Matters

Diabetic Ketoacidosis: A Persistent Threat

Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes that occurs when the body does not produce enough insulin, causing it to break down fat for energy instead of glucose. This process releases ketones into the bloodstream, making it dangerously acidic. DKA can disrupt vital organ function and, if left untreated, lead to death.

DKA is most common in people with Type 1 Diabetes (T1D), but it also occurs in Type 2 Diabetes (T2D), particularly during illness, medication non-adherence, or when using SGLT2 inhibitors. Hospitalizations for DKA have been increasing in many countries, driven in part by the rising prevalence of diabetes and the growing use of medications that can predispose to ketone accumulation.

Abbott shared study data in early 2026 outlining the growing burden of DKA, providing part of the clinical justification for the Libre Duo system. The core argument: current ketone monitoring relies on fingerstick blood tests or urine dipsticks that capture only a single moment in time. By the time ketone levels are detected through these methods, patients may already be in metabolic crisis.

The Clinical Case for Continuous Ketone Monitoring

Continuous glucose monitoring (CGM) has transformed diabetes management over the past decade by providing real-time glucose data, trend arrows, and alerts for hypo- and hyperglycemia. But CGM addresses only half of the metabolic equation. Ketone monitoring has remained a separate, intermittent process.

The Libre Duo system addresses this gap by integrating continuous ketone sensing alongside glucose monitoring in a single wearable sensor. The clinical benefit is straightforward: continuous ketone data enables earlier detection of rising ketones, allowing patients and clinicians to intervene before DKA develops — rather than reacting to a metabolic emergency that has already occurred.

Key clinical scenarios where continuous ketone monitoring provides value beyond standard CGM include:

• Infusion set failure or blocked/kinked cannulas in insulin pump users, where insulin delivery is interrupted but glucose has not yet risen enough to trigger a CGM alert
• Illness-related insulin resistance, where metabolic stress drives ketone production even when glucose appears moderately controlled
• Overnight insulin interruption, when patients are sleeping and cannot check ketones manually
• Unexplained persistent hyperglycemia that does not respond as expected to corrective insulin doses
• Active children and adolescents, whose variable activity levels and food intake create metabolic volatility

Both Libre Duo sensors deliver consistent, strong accuracy for glucose and ketone measurements. The integration with Abbott's Libre digital health ecosystem enables users to share glucose and ketone data with caregivers and healthcare providers through connected apps and cloud-based reporting platforms.

Regulatory Strategy: Dual-Analyte Biowearable Under EU MDR

CE Marking Under EU MDR

The Libre Duo systems received CE marking under the EU Medical Device Regulation (EU 2017/745). As implantable-class (or more precisely, invasive body-contact) devices that monitor a critical physiological parameter, CGM sensors are typically classified as Class IIb under MDR Annex VIII classification rules.

For a dual-analyte sensor that monitors both glucose and ketones, the regulatory strategy required:

1. Demonstrating analytical accuracy for both analytes independently: Each measurement channel — glucose and ketones — must meet accuracy standards for the intended clinical decisions. For glucose, this includes MARD (Mean Absolute Relative Difference) benchmarks against reference methods. For ketones, the analytical performance must support the detection of rising β-hydroxybutyrate levels that precede DKA.

2. Clinical validation for the combined intended use: The clinical data package must demonstrate that continuous dual monitoring provides clinically meaningful benefits compared to standard CGM alone, particularly for DKA prevention and earlier metabolic intervention.

3. Safety analysis for dual-analyte risk: The risk management file (per ISO 14971) must address risks specific to dual-analyte monitoring — including the potential for conflicting or misleading trend information if one analyte channel degrades while the other remains functional.

4. Integration with the Libre ecosystem: Software features (alerts, trend displays, data sharing) that combine glucose and ketone information must be validated under IEC 62304 and IEC 62366 for usability.

FDA Pathway: What to Expect

For the U.S. market, the Libre Duo systems are under FDA review. The likely regulatory pathway is a PMA supplement or 510(k) — depending on how FDA views the relationship between the Libre Duo and Abbott's existing FreeStyle Libre platform:

• If FDA considers the ketone sensing capability to be a significant change to an existing PMA device, a PMA supplement would be required. This is the most likely pathway, given that Abbott's FreeStyle Libre systems are Class III PMA devices.
• If the dual-analyte sensor is viewed as sufficiently similar to a legally marketed predicate with only incremental changes, a 510(k) could potentially apply — though this is unlikely for a device adding an entirely new analyte to a life-sustaining monitoring system.

The FDA's review will focus on:

• Analytical accuracy of the ketone channel compared to reference laboratory β-hydroxybutyrate measurement
• Clinical data demonstrating DKA detection or prevention benefits
• Alert algorithm performance (sensitivity and specificity for clinically significant ketone thresholds)
• Pediatric performance data (for the Libre Duo 10 Day indication in patients ages 2+)
• Cybersecurity and data integrity for the connected platform

The CGM Market in 2026: Abbott, Dexcom, and the Battle for the Next Generation

Abbott's Diabetes Care Division

Abbott's diabetes care division remains a key revenue driver within its medtech portfolio, supported by strong global adoption of the FreeStyle Libre product line. In fiscal year 2025, the diabetes care segment generated revenues of nearly $8 billion, topping FY24 values by 17.5% — despite a rocky Q4 2025 clouded by a broader sales miss.

The Libre product family now spans:

• FreeStyle Libre 3+: Abbott's current-generation CGM sensor, available OTC in some markets, with 14-day wear and minute-by-minute readings
• Libre Duo / Libre Duo 10 Day: The new dual glucose-ketone sensors (CE marked, FDA pending)
• Libre digital health ecosystem: Connected apps, cloud-based reporting, data sharing with providers and caregivers
• Integration with automated insulin delivery (AID) systems: Abbott is working with leading pump companies to connect Libre sensors with insulin pumps for hybrid closed-loop systems

Dexcom: The U.S. Market Leader

Dexcom is the leading CGM provider in the U.S. market. The San Diego-based company has been expanding aggressively into wellness applications through device integrations and digital partnerships:

• Dexcom G7: The current-generation CGM sensor, now natively integrated with the Apple Watch — a significant consumer-facing milestone
• Dexcom G8 platform: Outlined at the company's May 2026 Investor Day, the G8 platform features an updated algorithm with enhanced accuracy, 15-day wear time (a new baseline for Dexcom's portfolio), and sensor architecture designed to support additional analytes beyond glucose over time. The international launch of the extended-wear G7 is expected to begin in the second half of 2026.
• Dexcom Stelo: The first FDA-cleared CGM specifically for non-diabetic wellness users, with 15-day wear at $89/month OTC
• Oura partnership: Dexcom invested $75 million in Oura in November 2024, forging a partnership to integrate CGM data with Oura ring wellness metrics (sleep, stress, cardiovascular data). The combined data provides users insights into how sleep affects glucose variability and what meals cause glucose spikes.

Dexcom is also advancing EHR integration, working to bring CGM data directly into clinical workflows through platforms like Epic MyChart — addressing a long-standing barrier to clinician adoption.

Medtronic and Senseonics

Medtronic's Guardian 4 sensor remains in the CGM market but has lost ground to Abbott and Dexcom in standalone CGM. Medtronic's primary CGM strategy is now focused on integration with its insulin pump systems for automated insulin delivery.

Senseonics is pursuing an implantable CGM strategy with the Eversense 365 — a subcutaneously implanted sensor with 365-day wear. The Eversense 365 targets patients committed to long-term monitoring who prefer a "set-and-forget" approach. In May 2026, Senseonics' CEO discussed plans to compete with Dexcom and Abbott through continued innovation in implantable sensor technology.

Market Size and Growth

The global continuous glucose monitoring market is expected to post healthy, near double-digit growth over the next decade. The CGM for wellness market alone (non-diabetic consumers using CGM for metabolic optimization) reached approximately $3.8 billion in 2025, with wearable devices commanding 67.4% of global revenues. This market is projected to grow at a 12.4% CAGR through 2034.

Key growth drivers include:

• Expanding CGM access to Type 2 diabetes patients not on insulin
• OTC regulatory approvals opening the consumer wellness market
• Integration with smartwatches (Apple Watch, Garmin) and smart rings (Oura)
• Insurance and Medicare coverage expansion for CGM in broader patient populations
• Growing interest in metabolic health monitoring driven by GLP-1 medication use

The Convergence of Wearables and Medical Devices

Oura Ring 5: Consumer Wearables Getting Medical Features

The Abbott Libre Duo CE mark coincides with another significant development in the wearable-meets-medical-device space: Oura's launch of the Ring 5 on June 4, 2026.

The Oura Ring 5 — 40% smaller than its predecessor — adds AI-powered health features including blood pressure pattern detection, GLP-1 medication tracking, and brain health monitoring. Oura, valued at $11 billion following a $900 million Series E funding round in October 2025, confidentially filed for IPO on May 21, 2026. CEO Tom Hale projected the company is on track for $2 billion in sales in 2026.

Oura's partnership with Dexcom exemplifies the convergence trend: CGM data integrated with smart ring wellness metrics creates a multi-modal health monitoring platform that spans clinical and consumer applications. Oura has also partnered with Mira, a femtech company, to provide lab-grade hormone testing data to Oura ring users.

Regulatory Implications of Convergence

The trend toward consumer wearables with medical-grade features raises important regulatory questions:

1. Where is the line between wellness and medical device? Oura's blood pressure pattern detection and GLP-1 tracking may or may not cross the threshold into medical device territory, depending on the intended use claims and the clinical decisions the data informs.

2. FDA General Wellness Policy: The FDA's 2026 guidance on general wellness devices provides a framework for distinguishing between low-risk wellness products (which do not require premarket review) and medical devices. Products that make disease-specific claims or inform clinical treatment decisions are medical devices.

3. Dual-analyte and multi-modal platforms: As wearable platforms integrate more sensors (glucose, ketones, blood pressure, temperature, hormones, activity), the regulatory complexity increases. Each new analyte or clinical feature may change the device's classification, require additional clinical evidence, or trigger new cybersecurity requirements.

4. Connected ecosystem regulation: When a CGM sensor connects to a smart ring, which connects to an insulin pump, which connects to a cloud platform — the regulatory responsibility spans multiple manufacturers. The FDA's approach to interoperable device systems (including the Digital Health Center of Excellence's work on device software functions) is evolving to address these multi-component systems.

What Comes Next in Continuous Metabolic Monitoring

Multi-Analyte Sensors

Abbott's Libre Duo is the first commercially approved dual-analyte biowearable, but it will not be the last. Dexcom's G8 platform architecture is designed to support additional analytes beyond glucose over time, and ketone monitoring is part of the longer-term vision for multiple CGM manufacturers.

Future multi-analyte platforms may combine:

• Glucose and ketones ( Abbott Libre Duo — now available)
• Glucose and lactate (for exercise and critical care monitoring)
• Glucose, ketones, and alcohol (for metabolic research)
• Multiple metabolic markers integrated with AI-driven health analytics

Each new analyte layer adds regulatory complexity: the manufacturer must demonstrate analytical and clinical validity for each channel independently and in combination, and the risk management file must address interactions between channels.

Implantable Sensors

Senseonics' Eversense 365 demonstrates that implantable CGM is viable for long-term use. Future implantable platforms may extend to multi-analyte monitoring, providing truly continuous metabolic data without the need for regular sensor changes. The regulatory pathway for implantable multi-analyte sensors will likely require PMA approval with long-term safety data.

Non-Invasive CGM

Several companies are pursuing non-invasive glucose monitoring through optical, electromagnetic, or thermal methods. While none have achieved the clinical accuracy required for medical device clearance, the technology continues to advance. PKvitality's K'Track wristband is in commercial pilot phases in select European markets, with full consumer availability expected by 2026–2027.

Conclusion

Abbott's Libre Duo CE mark represents more than a new product launch — it marks the beginning of the multi-analyte biowearable era. The dual glucose-ketone sensor demonstrates that continuous monitoring platforms can expand beyond single-analyte limitations to address broader clinical needs, and that the regulatory framework (at least in the EU under MDR) can accommodate dual-analyte devices.

The competitive dynamics are equally significant. Abbott and Dexcom are in a technology race that is expanding CGM from a diabetes-specific tool into a broader metabolic health platform, integrating with consumer wearables (Oura, Apple Watch), pharmacy (OTC access), and clinical workflows (EHR integration). The Libre Duo CE mark gives Abbott a first-mover advantage in continuous ketone monitoring — a lead that competitors will work to close through their own multi-analyte sensor platforms.

For regulatory professionals, the message is clear: the next generation of continuous monitoring devices will be multi-analyte, multi-platform, and interconnected. The regulatory strategies that worked for single-analyte CGM sensors will need to evolve to address dual-analyte clinical evidence, wearable ecosystem cybersecurity, consumer-medical device boundary questions, and the intersection of OTC and prescription pathways.

Related reading: For wearable medical device regulatory pathways, see our Wearable Medical Devices Regulatory Guide. For drug-device combination product regulatory strategies, see our GLP-1 Drug Delivery Device Guide. For EU MDR CE marking requirements, see our CE Marking Guide.